Semler to Participate in the H.C. Wainwright Global Life Sciences Conference
Semler Scientific, Inc. (SMLR) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Semler Scientific, Inc. (SMLR) announced its participation in the H.C. Wainwright Global Life Sciences Conference. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview on March 9, 2021, accessible on-demand at semlerscientific.com/hcwr-global. Additionally, management will engage in one-on-one investor calls on March 10. Semler specializes in technology solutions for improving clinical effectiveness, focusing on chronic disease evaluation.
Details
News Market Reaction – SMLR
The recorded move for SMLR in the trading session of this news was -1.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., Feb. 25, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian, and chief marketing officer, Dennis Rosenberg, will present a company overview at the H.C. Wainwright Global Life Sciences Conference.
The presentation will be available on-demand beginning March 9, at 7:00 am ET and may be accessed through the following link: http://www.semlerscientific.com/hcwr-global. The presentation will be archived for a period of 90 days after the conference. Management will also participate in 1-on-1 calls with investors on March 10 during the conference.
About Semler Scientific, Inc.
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific's mission is to develop, manufacture and market innovative proprietary products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011, and received FDA 510(k) clearance for QuantaFlo®, the next generation version of this product, in 2015. QuantaFlo® is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo® is used by Semler Scientific's customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.
CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650
View original content:http://www.prnewswire.com/news-releases/semler-to-participate-in-the-hc-wainwright-global-life-sciences-conference-301235401.html
SOURCE Semler Scientific, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.